BGB-11417-301 Protocol title: A Phase 3 Open-Label Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Chronic Lymphocytic Leukemia
  • Age: Between 18 Year(s) - 90 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Confirmed diagnosis of CLL
    2. Lymphocyte count = 5000 cells/µL at time of CLL diagnosis
    3. Life expectancy over 6 months

You may not be eligible for this study if the following are true:

    1. Known prolymphocytic leukemia or history of, or currently suspected, Richter’s transformation
    2. Known central nervous system involvement
    3. Patients with a history of confirmed progressive multifocal leukoencephalopathy (PML)



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.